Fresh analysis suggests that people who discontinue new weight-loss injections like semaglutide or tirzepatide may regain reduced body mass far faster than those who stop conventional lifestyle programs.
Research printed in a leading medical journal points out that while obese individuals often shed about a fifth of their total mass while undergoing treatment, the weight is regained at an average rate of nearly a kilo each month once they quit.
"Individuals buying such treatments need to be cognizant of the danger of rapid rebound weight gain when the therapy concludes," cautioned expert Dr. Susan Jebb.
That rate of recovery suggests a return to original mass within about a year and a half.
Weighing Therapies
The study, which examined dozens of trials involving thousands of patients, compared the outcomes of these new drugs with older methods.
Scientists note that individuals who lose weight through dieting generally have a less rapid creep back—approximately 100 grams monthly—post-intervention.
Explaining the Rapid Rebound
Experts believe the mode of action of the drugs accounts for the heightened regain.
GLP-1 drugs mimic a body's own chemical called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal could lead to the system to generate a reduced amount of its endogenous GLP-1, and could reduce sensitivity to its effects," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this hormone supplement leads to hunger is unsuppressed, making overeating much more probable."
A Lifelong Issue?
Health authorities recommend the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
Professionals say that, considering the likelihood of relapse, the treatment should be considered life-long.
This perspective is echoed by pharmaceutical companies, who state that the results "highlight the long-term character of excess weight," similar to managing conditions like diabetes.
Patient Testimonies
Users who have discontinued the medication report a powerful resurgence of appetite.
"It felt as if something that goes on and you become ravenous," said one woman.
This challenge is compounded if individuals have not established lasting dietary or behavioural modifications during treatment.
Widespread Interest
Survey data show that a significant number of adults in the UK have tried these injections in the past year, with desire continuing to grow.
- Adoption is greater among females than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion obtain the medications through private prescriptions rather than the NHS.
In conclusion, researchers emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a standalone fix and long-term success likely depends on ongoing behavioural support.
